Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<ul>
<li>Historically, <a href="https://www.smartkarma.com/entities/cp-all-pcl" target="_blank" data-smartkarma-citation="entities:13889:1" rel="noopener">CP ALL PCL (CPALL TB)</a> share price has proved to be more defensive than the peers. </li>
<li>Thanks to its vast coverage, the business is the direct beneficiary of the Thai Help Thai program, which supports daily living and B2B through mom-and-pop shops.</li>
<li>Market share and margins are expected to expand thanks to the partnership with the Thai government. </li>
</ul>


Historically, CP ALL PCL (CPALL TB) share price has proved to be more defensive than the peers. 
Thanks to its vast coverage, the business is the direct beneficiary of the Thai Help Thai program, which supports daily living and B2B through mom-and-pop shops.
Market share and margins are expected to expand thanks to the partnership with the Thai government. 


Founder at Stock Spin-off Investing, Stock Spin-Off Investing

Richard Howe

Founder at Stock Spin-off Investing

Stock Spin-Off Investing

Generate attractive returns by taking advantage of inefficiencies in the stock spin-off market.

Stock Spin-offs

Event-Driven

<ul><li><p>The Wall Street Journal recently published <a href="https://www.wsj.com/business/media/streaming-prices-are-soaringand-consumers-are-still-paying-1bb7dbae?gaa_at=eafs&amp;gaa_n=AWEtsqerMaDRe0nUfUrSt2xrfSfCVuLx_ceJQsAUdBpc-rAhTsWuMKpo2YO_&amp;gaa_sig=4Cd9WfQr_CT1KGN0vDrLDYLksGu89gwWcpzYMWzVh2bkvmNwVFHiBWViDESQRiKPyLxoZINiok8yJX8rUPbQXg%3D%3D&amp;gaa_ts=691747da" target="_blank" rel="noopener">a good article</a> highlighting that streaming costs are soaring but consumers continue to be willing to pay.</p><figure class="editor-figure mceNonEditable"></figure></li><li>This is good news for Starz (STRZ), a pure play streaming service that is relatively cheap vs. its larger competitors.</li><li>I continue to think Starz looks attractive. It is showing sequential revenue growth and OTT subscriber growth yet trades at 3.7x EBITDA and 2x FCF.</li></ul>

The Wall Street Journal recently published a good article highlighting that streaming costs are soaring but consumers continue to be willing to pay.This is good news for Starz (STRZ), a pure play streaming service that is relatively cheap vs. its larger competitors.I continue to think Starz looks attractive. It is showing sequential revenue growth and OTT subscriber growth yet trades at 3.7x EBITDA and 2x FCF.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Unilever has reported its financial results for the first half of 2025, showcasing several strategic advancements and challenges across various business sectors and geographic regions.</li><li>These results are marked by an underlying sales growth of 3.4% for the half-year, a commendable balance between volume and price increases.</li><li>The company has successfully achieved volume improvements, indicating a strategic focus on maintaining competitive edge and operational efficiency despite prevailing subdued market conditions.</li></ul>

Unilever has reported its financial results for the first half of 2025, showcasing several strategic advancements and challenges across various business sectors and geographic regions.These results are marked by an underlying sales growth of 3.4% for the half-year, a commendable balance between volume and price increases.The company has successfully achieved volume improvements, indicating a strategic focus on maintaining competitive edge and operational efficiency despite prevailing subdued market conditions.

Unilever PLC: How Are They Executing Portfolio Transformation Through M&A and Divestments!

<ul><li>The recent performance of Unilever highlights both strengths and potential challenges for the company.</li><li>The full year results for 2024 demonstrate a notable recovery, characterized by an overall increase in gross margin and consistent volume growth across various business segments.</li><li>Unilever's Growth Action Plan (GAP), launched in late 2023, appears to be yielding results, reflected in the underlying sales growth of 4.2%, driven by volume growth of 2.9% and pricing contributions of 1.3%.</li></ul>

The recent performance of Unilever highlights both strengths and potential challenges for the company.The full year results for 2024 demonstrate a notable recovery, characterized by an overall increase in gross margin and consistent volume growth across various business segments.Unilever's Growth Action Plan (GAP), launched in late 2023, appears to be yielding results, reflected in the underlying sales growth of 4.2%, driven by volume growth of 2.9% and pricing contributions of 1.3%.

Unilever PLC: Growth in Beauty & Wellbeing & Personal Care Segments Propelling Our ‘Outperform’ Rating!

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>
<a href="https://www.smartkarma.com/entities/blue-jet-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:36373:1" rel="noopener">Blue Jet Healthcare Ltd (BJHC IN)</a> is a science-led pharmaceutical company that has evolved into a strategic partner for the CDMO of advanced Pharmaceutical Intermediates and APIs.</li>
<li>Company gave a record breaking Q3FY25 primarily driven by capacity expansion in Contrast media and PI Segment. Strong demand for the cardiovascular product was also witnessed.</li>
<li>Company commissioned an additional manufacturing block during Q3 FY25 at Ambernath for manufacturing Advance Contrast Media with investment around Rs. 100Mn.</li>
</ul>



Blue Jet Healthcare Ltd (BJHC IN) is a science-led pharmaceutical company that has evolved into a strategic partner for the CDMO of advanced Pharmaceutical Intermediates and APIs.
Company gave a record breaking Q3FY25 primarily driven by capacity expansion in Contrast media and PI Segment. Strong demand for the cardiovascular product was also witnessed.
Company commissioned an additional manufacturing block during Q3 FY25 at Ambernath for manufacturing Advance Contrast Media with investment around Rs. 100Mn.


The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

United Kingdom

Unilever is a British multinational consumer goods company that manufactures and sells a wide range of products including foods, condiments, home care, and personal care items. Its portfolio includes approximately 400 brands, with key segments in Beauty & Wellbeing, Personal Care, Home Care, and Nutrition. The company is headquartered in London, England, and was founded in 1929 through the merger of Margarine Unie and Lever Brothers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Unilever (UL US)

CPALL: Beneficiary Of Thai Help Thai

CP ALL PCL's defensive share price, vast coverage, and partnership with the Thai government position it well for growth and expansion in the market.

Henry Soediarko

Weekly Update (MICC, MEDXF, STRZ)

The Wall Street Journal recently published a good article highlighting that streaming costs are soaring but consumers continue to be willing to...

Richard Howe

Unilever PLC: How Are They Executing Portfolio Transformation Through M&A and Divestments!

Unilever has reported its financial results for the first half of 2025, showcasing several strategic advancements and challenges across various...

Baptista Research

Unilever PLC: Growth in Beauty & Wellbeing & Personal Care Segments Propelling Our ‘Outperform’ Rating!

The recent performance of Unilever highlights both strengths and potential challenges for the company. The full year results for 2024 demonstrate...

Baptista Research

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

Blue Jet Healthcare Ltd saw record-breaking Q3FY25 results due to capacity expansion in Contrast media and PI Segment, with strong demand for...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

CPALL: Beneficiary Of Thai Help Thai

​CP ALL PCL's defensive share price, vast coverage, and partnership with the Thai government position it well for growth and expansion in the market.

Henry Soediarko

Weekly Update (MICC, MEDXF, STRZ)

The Wall Street Journal recently published a good article highlighting that streaming costs are soaring but consumers continue to be willing to...

Richard Howe

Unilever PLC: How Are They Executing Portfolio Transformation Through M&A and Divestments!

Unilever has reported its financial results for the first half of 2025, showcasing several strategic advancements and challenges across various...

Baptista Research

Unilever PLC: Growth in Beauty & Wellbeing & Personal Care Segments Propelling Our ‘Outperform’ Rating!

The recent performance of Unilever highlights both strengths and potential challenges for the company. The full year results for 2024 demonstrate...

Baptista Research

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

​Blue Jet Healthcare Ltd saw record-breaking Q3FY25 results due to capacity expansion in Contrast media and PI Segment, with strong demand for...

Sudarshan Bhandari

CP ALL PCL's defensive share price, vast coverage, and partnership with the Thai government position it well for growth and expansion in the market.

Blue Jet Healthcare Ltd saw record-breaking Q3FY25 results due to capacity expansion in Contrast media and PI Segment, with strong demand for...